Physician profile
John Hunt
NPI 1508881533
$2,138.18
in general payments reported to CMS, 2019-2025
21 companies · $52.04 in 2025
The $52.04 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $916 · 2021: $134 · 2022: $66.64 · 2023: $112 · 2024: $27.54 · 2025: $52.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $153 · Education: $38.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $153.01 |
| Education | $38.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $560.61 | 2019-2025 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $324.67 | 2019-2023 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.18 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $177.08 | 2019-2020 | |
| Glaxosmithkline, LLC. | $153.69 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $111.47 | 2019 | |
| Amgen INC. | $107.00 | 2019-2021 | |
| Medtronic USA, INC. | $86.87 | 2019 | |
| Janssen Pharmaceuticals, INC | $72.13 | 2019-2020 | |
| Pfizer INC. | $69.75 | 2019-2020 | |
| Abbott Laboratories | $66.64 | 2022 | |
| Astellas Pharma US INC | $42.66 | 2019 | |
| Eisai INC. | $34.92 | 2020 | |
| Lilly USA, LLC | $29.14 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $27.34 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $17.53 | 2020 | |
| Zyla Life Sciences, INC. | $14.63 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.21 | 2020 | |
| Daiichi Sankyo INC. | $11.78 | 2019 | |
| Merck Sharp & Dohme LLC | $11.09 | 2020 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.